WO2009030676A3 - Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age - Google Patents
Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age Download PDFInfo
- Publication number
- WO2009030676A3 WO2009030676A3 PCT/EP2008/061527 EP2008061527W WO2009030676A3 WO 2009030676 A3 WO2009030676 A3 WO 2009030676A3 EP 2008061527 W EP2008061527 W EP 2008061527W WO 2009030676 A3 WO2009030676 A3 WO 2009030676A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- age
- years
- pharmaceutical composition
- vaccination
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention relates to a pharmaceutical composition comprising a cell culture derived, inactivated JEV for use in the treatment or prevention of an infection with JEV in a human subject with at least 40 years of age.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07115557 | 2007-09-03 | ||
EP07115557.6 | 2007-09-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009030676A2 WO2009030676A2 (en) | 2009-03-12 |
WO2009030676A3 true WO2009030676A3 (en) | 2009-07-02 |
Family
ID=40404491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/061527 WO2009030676A2 (en) | 2007-09-03 | 2008-09-02 | Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009030676A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010137036A2 (en) * | 2009-05-25 | 2010-12-02 | Panacea Biotec Ltd | Novel japanese encephalitis vaccine and method of manufacturing the same |
CA2763919C (en) | 2009-06-04 | 2017-05-23 | Rotation Medical, Inc. | Apparatus for fixing sheet-like materials to a target tissue |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001076624A1 (en) * | 2000-04-07 | 2001-10-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Inactivated japanese b encephalitis vaccine and process for producing the same |
-
2008
- 2008-09-02 WO PCT/EP2008/061527 patent/WO2009030676A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001076624A1 (en) * | 2000-04-07 | 2001-10-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Inactivated japanese b encephalitis vaccine and process for producing the same |
Non-Patent Citations (4)
Title |
---|
LYONS ET AL: "A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 17, 5 April 2007 (2007-04-05), pages 3445 - 3453, XP022022123, ISSN: 0264-410X * |
SCHIOLER K.L., SAMUEL M & WAI K.L.: "Vaccines for preventing Japanese encephalitis (review)", COCHRANE DATABASE SYST REV, vol. 3, no. CD004263, 18 July 2007 (2007-07-18), XP002518555, Retrieved from the Internet <URL:http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004263/pdf_fs.html> [retrieved on 20090310] * |
SCHULLER E ET AL: "Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 26, no. 34, 12 August 2008 (2008-08-12), pages 4382 - 4386, XP023179650, ISSN: 0264-410X, [retrieved on 20080617] * |
TAUBER ET AL: "Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 370, no. 9602, 29 November 2007 (2007-11-29), pages 1847 - 1853, XP022369933, ISSN: 0140-6736 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009030676A2 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010001733A (en) | Imidazopyrazine compounds. | |
WO2007002470A3 (en) | Inactivated chimeric vaccines and related methods of use | |
WO2007057763A3 (en) | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant | |
WO2010085100A3 (en) | Novel cellular transmembrane domain and intracellular transduction system containing the same | |
PH12017501075A1 (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
NZ607477A (en) | Non-natural amino acid replication-dependent microorganisms and vaccines | |
WO2007006712A3 (en) | Mycoplasma subunit vaccine | |
PH12015501637A1 (en) | Inactivated dengue virus vaccine with aluminium-free adjuvant | |
WO2009129470A3 (en) | Methods for treating herpes virus infections | |
IL224048B (en) | Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease | |
PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
HK1145149A1 (en) | Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection | |
EP2471926A3 (en) | Immunostimulatory oligodeoxynucleotides | |
WO2013048153A3 (en) | Binding molecule having influenza a virus-neutralizing activity produced from human b cell | |
WO2008149802A1 (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
MX2009012922A (en) | Intradermal hpv peptide vaccination. | |
WO2009005040A1 (en) | Pseudomonas aeruginosa outer membrane protein pa4710 | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
EP2495252A3 (en) | Soluble forms of hendra and nipah virus G glycoprotein | |
WO2010041241A3 (en) | Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding | |
WO2007147623A3 (en) | A novel target in the treatment of cytokine release syndrome | |
WO2009030676A3 (en) | Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age | |
WO2010039924A3 (en) | Th1 vaccination priming for active immunotheraphy | |
IL208862A (en) | Use of a protein capable of stimulating an immune response against a tat protein in the preparation of a medicament for preventing or treating acquired immunodeficiency syndrome (aids) in a patient and a composition and vaccine related thereto | |
NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08803502 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08803502 Country of ref document: EP Kind code of ref document: A2 |